Nidan,
Thanks again for the shout out. Here’s one thing we have both discussed before, the big picture view versus the details. I think we agree they are equally important but vastly different skill set, imo.
This is not passing the buck or a dodge, but I can truthfully say that falconer has a much better grasp on the fine details of the restoration of cellular homeostasis and he has painstakingly broken it all down for us in many insightful and readable but knowledgeable posts on several occasions.
I would defer to him in that area of expertise, either by reading some of his older posts, I think some are on the sticky compilation, or asking him to explain it anew.
I have a ton of respect for his knowledge...all of mine is borrowed from other sources which sometimes allow me to put things together but not take them apart, as others do so well.
I think both skills are necessary, valuable, and complimentary, but few folks, imo, possess both views in significant amounts.
Let me call upon falconer to share his knowledge/expertise in this field in answer to your question. If he is busy or otherwise unable, I’ll take my best stab, which will end up being links to the research of others in the field.
If you were to ask about the big picture strategy of how I think the trials will pan out - I got that one in the chamber. Short answer, we will should pass PDD easily, AD should also clear a comfortable margin and Rett appears promising but is the one I have some concerns over, to be truthful.
I’m confident that Anavex’s team has things figured out...I just don’t, at this point.
Also, I am willing to speculate on where Anavex would fit into the picture of a partnership or buyout and when, which I’ve posted before, but this field is in constant flux. I think we have reason to be optimistic about our prospects in this area as well - and I have faith in management that they are making all the right moves.
Best to you, Nidan...I think as another “big picture”, “survey the field depth” guy, you will understand my hesitations to narrow down to ground view and put everyone at a disadvantage.
Respect and regards always, bud.
Bio
Market Data 
Markets 
AI
